Verificando…
Traducido automáticamente. Dosis y advertencias: consulta el original en inglés. Leer en inglés
Inicio / Registrado en Nigeria / Neostigmine Methylsulphate Injection

Neostigmine Methylsulphate Injection

NAFDAC Reg. No. A4-7212 Estupefaciente

Registrado en NAFDAC. Registro activoAs of 4 November 2026 · synced automatically from official sources.
Producto
Neostigmine Methylsulphate Injection
Número NAFDAC
A4-7212
Principio activo
Neostigmine
Dosis
2.5 mg/mL
Forma
Solution for injection
Tamaño del envase
10 x 1 mL ampoules
Fabricante
No Constan
Solicitante (titular)
Chez Resources Pharmaceutical Limited
Approved
28 Feb 2025
Estado
Activo Ver en NAFDAC ↗
Registro válido hasta
27 Feb 2030
Alertas de la OMS
No se ha encontrado ninguno
Informes de la comunidad
Ninguno
Tiempos comprobados
0

Pero sobre el medicamento, Neostigmine: uses, dosage and brands worldwide

Lo que encontramos

  • Neostigmine Methylsulphate Injection is on the NAFDAC register with an active registration (A4-7212). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generado automáticamente a partir del registro NAFDAC, QUIÉN alerta y los datos de la comunidad a partir de hoy. Este no es un consejo médico. Siga siempre a su médico o farmacéutico.

How to use Neostigmine Methylsulphate Injection

Lo que dice el prospecto oficial. Si te lo recetó un médico, sigue la receta. Si el prospecto de tu caja es distinto, manda el de tu caja.

Para quién es

Neostigmine methylsulfate injection is a cholinesterase inhibitor indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery. Neostigmine methylsulfate injection, a cholinesterase inhibitor, is indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents (NMBAs) after surgery (1) .

Cómo tomarlo y con qué frecuencia
  • Should be administered by trained healthcare providers • Peripheral nerve stimulator and monitoring for twitch responses should be used to determine when neostigmine methylsulfate injection should be initiated and if additional doses are needed • For reversal of NMBAs with shorter half-lives, when first twitch response is substantially greater than 10% of baseline, or when a second twitch is present: 0.03 mg/kg by intravenous route • For reversal of NMBAs with longer half-lives or when first twitch response is close to 10% of baseline: 0.07 mg/kg by intravenous route • Maximum total dosage is 0.07 mg/kg or up to a total of 5 mg (whichever is less) • An anticholinergic agent, e.g., atropine sulfate or glycopyrrolate, should be administered prior to or concomitantly with neostigmine methylsulfate injection 2.1
  • Important Dosage Information Neostigmine methylsulfate injection should be administered by trained healthcare providers familiar with the use, actions, characteristics, and complications of neuromuscular blocking agents (NMBA) and neuromuscular block reversal agents
  • Doses of neostigmine methylsulfate injection should be individualized, and a peripheral nerve stimulator should be used to determine the time of initiation of neostigmine methylsulfate injection and should be used to determine the need for additional doses
  • Neostigmine methylsulfate injection is for intravenous use only and should be injected slowly over a period of at least 1 minute. …
Fortalezas en las que viene

Neostigmine methylsulfate injection is available as • Injection: 0.5 mg/mL, 5 mg of neostigmine methylsulfate in 10 mL multiple- dose vials • Injection: 1 mg/mL, 10 mg of neostigmine methylsulfate in 10 mL multiple-dose vials Injection: 0.5 mg/mL and 1 mg/mL in 10 mL multiple-dose vials (3)

Infancia
  • Neostigmine methylsulfate injection is approved for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery
  • In pediatric patients of all ages
  • Recovery of neuromuscular activity occurs more rapidly with smaller doses of cholinesterase inhibitors in infants and children than in adults
  • However, infants and small children may be at greater risk of complications from incomplete reversal of neuromuscular blockade due to decreased respiratory reserve. …
Older adults

Because elderly patients are more likely to have decreased renal function, neostigmine methylsulfate injection should be used with caution and monitored for a longer period in elderly patients. The duration of action of neostigmine methylsulfate is prolonged in the elderly; however, elderly patients also experience slower spontaneous recovery from neuromuscular blocking agents. …

Talk to a doctor first if

Neostigmine methylsulfate injection is contraindicated in patients with: • known hypersensitivity to neostigmine methylsulfate (known hypersensitivity reactions have included urticaria, angioedema, erythema multiforme, generalized rash, facial swelling, peripheral edema, pyrexia, flushing, hypotension, bronchospasm, bradycardia and anaphylaxis). • peritonitis or mechanical obstruction of the intestinal or urinary tract. …

Medicines it may not mix with

The pharmacokinetic interaction between neostigmine methylsulfate and other drugs has not been studied. Neostigmine methylsulfate is metabolized by microsomal enzymes in the liver. Use with caution when using neostigmine methylsulfate injection with other drugs which may alter the activity of metabolizing enzymes or transporters.

Warnings

• Bradycardia: Atropine or glycopyrrolate should be administered prior to neostigmine methylsulfate injection to lessen risk of bradycardia. ( 5.1 ) • Serious Reactions with Coexisting Conditions: Use with caution in patients with, coronary artery disease, cardiac arrhythmias, recent acute coronary syndrome or myasthenia gravis. ( 5.2 ) • Neuromuscular Dysfunction: Can occur if large doses of neostigmine methylsulfate injection are administered when neuromuscular blockade is minimal; reduce dose if recovery from neuromuscular blockade is nearly complete. ( 5.4 ) 5.1. Bradycardia Neostigmine has been associated with bradycardia. …

Posibles efectos secundarios

Most common adverse reactions during treatment: bradycardia, nausea and vomiting ( 6) To report SUSPECTED ADVERSE REACTIONS, contact Dr. Reddy's Laboratories Inc., at 1-888-375-3784 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1. Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adverse reactions to neostigmine methylsulfate are most often attributable to exaggerated pharmacological effects, in particular, at muscarinic receptor sites. …

Pregnancy and breastfeeding

8.1 Pregnancy Risk Summary There are no adequate or well-controlled studies of neostigmine methylsulfate injection in pregnant women. It is not known whether neostigmine methylsulfate injection can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. The incidence of malformations in human pregnancies has not been established for neostigmine as the data are limited. …

If you take too much

Muscarinic symptoms (nausea, vomiting, diarrhea, sweating, increased bronchial and salivary secretions, and bradycardia) may appear with overdosage of neostigmine methylsulfate injection (cholinergic crisis), but may be managed by the use of additional atropine or glycopyrrolate. The possibility of iatrogenic overdose can be lessened by carefully monitoring the muscle twitch response to peripheral nerve stimulation. Should overdosage occur, ventilation should be supported by artificial means until the adequacy of spontaneous respiration is assured, and cardiac function should be monitored. …

Si olvidas una dosis

Tómala en cuanto te acuerdes, salvo que falte poco para la siguiente. En ese caso, sáltate la olvidada. Nunca tomes dos dosis a la vez para compensar. Revisa tu prospecto, porque algunos medicamentos son distintos.

From the official U.S. FDA label for this active ingredient. Your pack may have a different strength, so always read its leaflet. If a doctor prescribed it, follow the prescription. Ask a pharmacist if you are unsure. Label dated 2021-02-02.

Label for neostigmine, the active ingredient registered with NAFDAC.

Check your pack of Neostigmine Methylsulphate Injection

Add the expiry date on your pack for a full Trust Score.

O haz fotos de la caja
Te quedan 3 verificaciones gratis hoy Official sources: U.S. FDA · EMA (EU) · Health Canada · WHO alerts

About Neostigmine Methylsulphate Injection

What is in Neostigmine Methylsulphate Injection?

Neostigmine Methylsulphate Injection contains Neostigmine (2.5 mg/mL), as solution for injection, according to its NAFDAC registration record.

Is Neostigmine Methylsulphate Injection registered with NAFDAC?

Yes. Neostigmine Methylsulphate Injection is listed on the NAFDAC register under registration number A4-7212, and its registration is active as of 4 November 2026.

Has Neostigmine Methylsulphate Injection been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Neostigmine Methylsulphate Injection in our automatically synced alert list.

How can I check that my pack of Neostigmine Methylsulphate Injection is genuine?

Run a free authenticity scan with the NAFDAC number A4-7212, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

How do I take Neostigmine Methylsulphate Injection?

Follow your prescription or the leaflet in your pack. The official label says: • Should be administered by trained healthcare providers ( 2.1) • Peripheral nerve stimulator and monitoring for twitch responses should be used to determine when neostigmine methylsulfate injection should be initiated and if additional doses are needed ( 2.2 ) • For reversal of NMBAs with shorter half-lives, when first twitch response is substantially greater than 10% of basel…

What is Neostigmine Methylsulphate Injection used for?

Neostigmine methylsulfate injection is a cholinesterase inhibitor indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery. Neostigmine methylsulfate injection, a cholinesterase inhibitor, is indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents (NMBAs) after surgery (1) . (Summarised from the official U.S. FDA label for neostigmine. Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Neostigmine Methylsulphate Injection? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.